Bacterial brain

Why Sequoia is backing Cortexyme’s Alzheimer’s hypothesis by leading $76M round

Preclinical data backing Cortexyme Inc.’s hypothesis that a bacterial pathogen drives Alzheimer’s disease, combined with clinical safety data, convinced Sequoia Capital to lead the company’s $76 million series B.

The round closed on May 31 with participation from fellow

Read the full 385 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE